Skip to content
Peptigraph home

Survodutide Dosage: Doses Studied, Units and Chart

What doses of Survodutide have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / glucagon dual agonistUpdated
Doses studied
7 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of Survodutide used in published studies
DoseFrequency and routeStudy typeSource
3.6 mg or 6.0 mg (adjusted up) vs placeboonce weekly · subcutaneous · 76 weeksHuman RCTn = 725The New England journal of medicine 2026, PMID 42253238
3.6 mg or 6.0 mg vs placeboonce weekly · subcutaneous · 76 weeksHuman RCTn = 752The New England journal of medicine 2026, PMID 42820639
6.0 mg vs placebo (2:1)once weekly · subcutaneous · 48 weeksHuman RCTn = 216Nature medicine 2026, PMID 42252333
0.6, 2.4, 3.6 or 4.8 mg vs placeboonce weekly · subcutaneous · 46 weeksHuman RCTn = 387The lancet. Diabetes & endocrinology 2024, PMID 38330987
2.4, 4.8 or 6.0 mg vs placeboonce weekly · subcutaneous · 48 weeksHuman RCTn = 293The New England journal of medicine 2024, PMID 38847460
up to 0.3, 0.9, 1.8 or 2.7 mg once weekly, or 1.2 or 1.8 mg twice weekly, vs placebo or open-label semaglutide up to 1.0 mgonce or twice weekly · subcutaneous · 16 weeksHuman RCTn = 413Diabetologia 2024, PMID 38095657
single 0.3 mg dose; then escalated from 0.3 mg to 6.0 mgonce weekly (multiple-dose part) · subcutaneous · 24 weeks escalation plus 4 weeks maintenanceHuman uncontrolled trialJournal of hepatology 2024, PMID 38857788

Before anyone considers it

  • Survodutide is investigational and not approved for any use.
  • Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Common questions

Is Survodutide FDA approved?

No. Survodutide is investigational (investigational · phase 3) and not approved for any use.

More on Survodutide

ResultsStudy outcomes and when they were measured.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
  4. 4Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026
  5. 5Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026PMID 42252333Accessed 2 Oct 2026
  6. 6Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026
  7. 7A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
  8. 8Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia · 2024PMID 38095657Accessed 2 Oct 2026
  9. 9Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.Journal of hepatology · 2024PMID 38857788Accessed 2 Oct 2026
  10. 10PubMed search: survodutide[tiab] OR BI456906[tiab] (86 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (56 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.